Testing of new agents in childhood cancer preclinical models

Meeting summary

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, Malcolm A. Smith

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.

Original languageEnglish (US)
Pages (from-to)3646-3657
Number of pages12
JournalClinical Cancer Research
Volume8
Issue number12
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Education
Neoplasms
National Cancer Institute (U.S.)
Heterografts
Transgenic Mice
Pediatrics
Equipment and Supplies
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Houghton, P. J., Adamson, P. C., Blaney, S., Fine, H. A., Gorlick, R., Haber, M., ... Smith, M. A. (2002). Testing of new agents in childhood cancer preclinical models: Meeting summary. Clinical Cancer Research, 8(12), 3646-3657.

Testing of new agents in childhood cancer preclinical models : Meeting summary. / Houghton, Peter J.; Adamson, Peter C.; Blaney, Susan; Fine, Howard A.; Gorlick, Richard; Haber, Michelle; Helman, Lee; Hirschfeld, Steve; Hollingshead, Melinda G.; Israel, Mark A.; Lock, Richard B.; Maris, John M.; Merlino, Glenn; Patterson, Wendy; Reynolds, C. Patrick; Shannon, Kevin; Yu, Alice; Yu, John; Smith, Malcolm A.

In: Clinical Cancer Research, Vol. 8, No. 12, 01.12.2002, p. 3646-3657.

Research output: Contribution to journalArticle

Houghton, PJ, Adamson, PC, Blaney, S, Fine, HA, Gorlick, R, Haber, M, Helman, L, Hirschfeld, S, Hollingshead, MG, Israel, MA, Lock, RB, Maris, JM, Merlino, G, Patterson, W, Reynolds, CP, Shannon, K, Yu, A, Yu, J & Smith, MA 2002, 'Testing of new agents in childhood cancer preclinical models: Meeting summary', Clinical Cancer Research, vol. 8, no. 12, pp. 3646-3657.
Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M et al. Testing of new agents in childhood cancer preclinical models: Meeting summary. Clinical Cancer Research. 2002 Dec 1;8(12):3646-3657.
Houghton, Peter J. ; Adamson, Peter C. ; Blaney, Susan ; Fine, Howard A. ; Gorlick, Richard ; Haber, Michelle ; Helman, Lee ; Hirschfeld, Steve ; Hollingshead, Melinda G. ; Israel, Mark A. ; Lock, Richard B. ; Maris, John M. ; Merlino, Glenn ; Patterson, Wendy ; Reynolds, C. Patrick ; Shannon, Kevin ; Yu, Alice ; Yu, John ; Smith, Malcolm A. / Testing of new agents in childhood cancer preclinical models : Meeting summary. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 12. pp. 3646-3657.
@article{88a169326ced4c9581e1069e1735059c,
title = "Testing of new agents in childhood cancer preclinical models: Meeting summary",
abstract = "A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.",
author = "Houghton, {Peter J.} and Adamson, {Peter C.} and Susan Blaney and Fine, {Howard A.} and Richard Gorlick and Michelle Haber and Lee Helman and Steve Hirschfeld and Hollingshead, {Melinda G.} and Israel, {Mark A.} and Lock, {Richard B.} and Maris, {John M.} and Glenn Merlino and Wendy Patterson and Reynolds, {C. Patrick} and Kevin Shannon and Alice Yu and John Yu and Smith, {Malcolm A.}",
year = "2002",
month = "12",
day = "1",
language = "English (US)",
volume = "8",
pages = "3646--3657",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Testing of new agents in childhood cancer preclinical models

T2 - Meeting summary

AU - Houghton, Peter J.

AU - Adamson, Peter C.

AU - Blaney, Susan

AU - Fine, Howard A.

AU - Gorlick, Richard

AU - Haber, Michelle

AU - Helman, Lee

AU - Hirschfeld, Steve

AU - Hollingshead, Melinda G.

AU - Israel, Mark A.

AU - Lock, Richard B.

AU - Maris, John M.

AU - Merlino, Glenn

AU - Patterson, Wendy

AU - Reynolds, C. Patrick

AU - Shannon, Kevin

AU - Yu, Alice

AU - Yu, John

AU - Smith, Malcolm A.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.

AB - A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.

UR - http://www.scopus.com/inward/record.url?scp=0036896670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036896670&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 3646

EP - 3657

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -